ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives,
an Industry Supported Symposium at the 2024 SGO Annual Meeting

Activity Overview

The GOG Foundation, Inc., GOG Partners, Seagen Inc. and Genmab welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to register for access to the ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives Enduring Education Material, an Industry Supported Symposium during the 2024 SGO Annual Meeting on Women’s Cancer®.

This symposium was developed by The GOG Foundation, Inc. in partnership with Seagen, Inc. and Genmab.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

  • Review the current landscape for the treatment of recurrent cervix cancer based on pivotal clinical trial data and insights from 2023
  • Understand the role of ADC in cervix cancer, and how to educate patients on this novel treatment option
  • Review and incorporate updated data in treatment decision making through case based learning
  • Understand the patient perspective with respect to receiving treatments in recurrent cervix cancer

Moderator


Bhavana Pothuri, MD

Faculty


Leslie Randall, MD, MAS

Susana Campos, MD, MPH

Kathleen Lutz, NP

Andrea Kinlock, Patient Advocate

Agenda & Presentation Materials

ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives, an Industry Supported Symposium during the 2024 SGO Annual Meeting on Women’s Cancer®

Presented on Sunday, March 17, 2024 | 11:30 AM – 1:00 PM PT

Enurding Education Materials will be available for 6 months after the live presentation.

Register For Access To The Recording

11:30 am – 11:35 am
Welcome & Introduction – View Presentation
Bhavana Pothuri, MD, NYU Langone, Perlmutter Cancer Center, New York City, NY, USA
11:35 am – 11:55 am
Introduction to ADCs, Understanding the Mechanism of Action with a Case Presentation – View Presentation
Susana Campos, MD, MPH, Dana Farber Cancer Institute, Boston, MA, USA
11:55 am – 12:05 pm
TV 301 Phase III, PRO Data and Adverse Events – View Presentation
Leslie Randall, MD, MAS, Virginia Commonwealth University, Richmond, VA, USA
12:05 pm – 12:15 pm
Education, Adherence and Symptom Management in Patients with Cervix Cancer Treated with ADC Therapy – View Presentation
Kathleen Lutz, NP, NYU Langone, Perlmutter Cancer Center, New York City, NY, USA
12:15 pm – 12:30 pm
The Patient Perspective on Cervix Cancer and Treatment of Recurrence – View Presentation
Andrea Kinloch, Patient Advocate
12:30 pm – 12:55 pm
Panel Discussion and Q&A
All Facutly
12:55 pm – 1:00 pm
Closing Comments
All Faculty